Walmart to Cut PhonePe Stake in IPO as Tiger Global and Microsoft Exit 
Lynas Rare Earths Shares Surge as Quarterly Revenue Jumps on Strong Prices 
Baidu Shares Surge After Official Launch of Advanced Ernie 5.0 AI Model 
Sanofi Reports Positive Late-Stage Results for Amlitelimab in Eczema Treatment 
Ericsson Plans SEK 25 Billion Shareholder Returns as Margins Improve Despite Flat Network Market 
Tesla Plans FSD Subscription Price Hikes as Autonomous Capabilities Advance 
Trump Signs Executive Order to Limit Wall Street Investment in Single-Family Homes 
Memory Chip Shortage Drives Higher Gadget Prices and Weakens Global Tech Demand 
Elon Musk Shares Bold Vision for AI, Robots, and Space at Davos 
Global DRAM Chip Shortage Puts Automakers Under New Cost and Supply Pressure 
Nvidia CEO Jensen Huang Plans China Visit Amid AI Chip Market Uncertainty 
U.S. Vaccine Policy Shifts Under RFK Jr. Create Uncertainty for Pharma and Investors 
FAA Says It Is Not Blocking Boeing 737 MAX 7 and MAX 10 Certification 
ByteDance Finalizes Majority U.S.-Owned TikTok Joint Venture to Avert American Ban 
Court Allows Expert Testimony Linking Johnson & Johnson Talc Products to Ovarian Cancer 
Microsoft Restores Microsoft 365 Services After Widespread Outage 
SOUTH SAN FRANCISCO, Calif., May 03, 2017 -- Calithera Biosciences, Inc. (Nasdaq:CALA), a clinical-stage pharmaceutical company focused on discovering and developing novel small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer, today announced that the Company’s first quarter 2017 financial results will be released on Tuesday, May 9, 2017. Company management will host a conference call on Tuesday, May 9, 2017 at 1:30 p.m. Pacific Time/ 4:30 p.m. Eastern Time to discuss the financial results and other recent corporate highlights.
The press release and live audio webcast can be accessed via the Investor section of the Company’s website at www.calithera.com. The conference call can be accessed by dialing (855) 783-2599 (domestic) or (631) 485-4877 (international) and refer to conference ID 18046993. Please log in approximately 5-10 minutes before the event to ensure a timely connection. The archived webcast will remain available for replay on Calithera’s website for 30 days.
About Calithera Biosciences
Calithera Biosciences, Inc. is a clinical-stage pharmaceutical company focused on discovering and developing novel small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer. Calithera’s lead product candidate, CB-839, is a potent, selective, reversible and orally bioavailable inhibitor of glutaminase. CB-839 takes advantage of the pronounced dependency many cancers have on the nutrient glutamine for growth and survival. It is currently being evaluated in Phase 1/2 clinical trials in combination with standard of care agents. CB-1158 is a first-in-class immuno-oncology metabolic checkpoint inhibitor targeting arginase, a critical immunosuppressive enzyme responsible for T-cell suppression by myeloid-derived suppressor cells. Arginase depletes arginine, a nutrient that is critical for the activation, growth and survival of the body’s cancer-fighting immune cells, known as cytotoxic T-cells. CB-1158 is being developed in collaboration with Incyte Corporation and is currently in a Phase 1 clinical trial. Calithera is headquartered in South San Francisco, California. For more information about Calithera, please visit www.calithera.com.
CONTACT: Jennifer McNealey [email protected] 650-870-1071
